Skip to content

Commodore Capital LP

Follow

13F filer, CIK 1831942, NEW YORK, NY

Commodore Capital LP reported $1,290,641,676 across 37 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 65.24% of the portfolio.

Accepted , ingested 13F-HR 0001831942-26-000052

Period
2026-09-30
Reported value
$1.29B
Holdings
37
Top 10 weight
65.24%
New
11
Sold out
7

Part of the filer group Commodore Capital LP

  • Commodore Capital Master LP
  • Michael Kramarz
  • Robert Egen Atkinson
How groups are built

Stakes and trades reported after 2026-09-30

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • MTRI MENTARI THERAPEUTICS INC: 13G 2,977,630 shares, 5.6% of the class, 13G filed 2026-11-13, 0001831942-26-000046Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
DMRAnew+1,939,000$41.3M
SRZNnew+885,000$28.5M
KRSAnew+877,022$28.1M
SGMTnew+2,757,742$27.2M
ADRXnew+1,260,577$25.1M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
AMLXreduced-3,650,000-$106M
TNGXexited-2,250,000-$70.3M
EYPTexited-4,600,000-$65.8M
COGTreduced-1,785,000-$57.2M
DMRAexited-1,939,000-$50.4M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001831942-26-000052, largest first. % of portfolio is the value over $1,290,641,676, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 13,350,000 shares; 2025Q3: 17,000,000 shares; 2025Q4: 17,000,000 shares; 2026Q1: 17,000,000 shares; 2026Q2: 12,000,000 shares; 2026Q3: 12,000,000 shares 12,000,000$217M16.78%0Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 4,205,000 shares; 2025Q1: 4,675,000 shares; 2025Q2: 4,692,809 shares; 2025Q3: 4,692,809 shares; 2025Q4: 4,692,809 shares; 2026Q1: 3,275,000 shares; 2026Q2: 3,275,000 shares; 2026Q3: 3,275,000 shares 3,275,000$150M11.63%0Timeline
ALKSALKERMES PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,300,000 shares; 2025Q1: 1,950,000 shares; 2025Q2: 2,450,000 shares; 2025Q3: 3,096,754 shares; 2025Q4: 3,550,000 shares; 2026Q1: 4,200,000 shares; 2026Q2: 3,000,000 shares; 2026Q3: 2,875,360 shares 2,875,360$117M9.03%-124,640Timeline
ANROALTO NEUROSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,823,196 shares; 2026Q1: 2,723,196 shares; 2026Q2: 2,723,196 shares; 2026Q3: 2,723,196 shares 2,723,196$69.5M5.39%0Timeline
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,988,084 shares; 2025Q1: 1,988,084 shares; 2025Q2: 1,988,084 shares; 2025Q3: 1,988,084 shares; 2025Q4: 2,388,245 shares; 2026Q1: 1,912,380 shares; 2026Q2: 846,786 shares; 2026Q3: 700,000 shares 700,000$62.3M4.83%-146,786Timeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 4,075,478 shares; 2025Q4: 5,650,000 shares; 2026Q1: 5,650,000 shares; 2026Q2: 5,650,000 shares; 2026Q3: 2,000,000 shares 2,000,000$58.2M4.51%-3,650,000Timeline
LBRXLB PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,500,000 shares; 2025Q4: 1,500,000 shares; 2026Q1: 1,500,000 shares; 2026Q2: 1,500,000 shares; 2026Q3: 1,282,273 shares 1,282,273$49.2M3.81%-217,727Timeline
DMRADAMORA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,939,000 shares 1,939,000$41.3M3.2%newTimeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 6,881,629 shares; 2025Q1: 8,892,816 shares; 2025Q2: 2,311,164 shares; 2025Q3: 7,250,000 shares; 2025Q4: 2,196,845 shares; 2026Q1: 2,888,007 shares; 2026Q2: 3,050,000 shares; 2026Q3: 1,265,000 shares 1,265,000$40.5M3.14%-1,785,000Timeline
TYRATYRA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 950,000 shares; 2025Q2: 3,100,000 shares; 2025Q3: 3,375,000 shares; 2025Q4: 3,375,000 shares; 2026Q1: 2,475,000 shares; 2026Q2: 1,875,000 shares; 2026Q3: 1,725,000 shares 1,725,000$37.7M2.92%-150,000Timeline
CLDXCELLDEX THERAPEUTICS INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 3,200,000 shares; 2025Q2: 3,450,000 shares; 2025Q3: 3,028,335 shares; 2025Q4: 2,565,000 shares; 2026Q1: 2,696,616 shares; 2026Q2: 1,350,000 shares; 2026Q3: 1,000,000 shares 1,000,000$32.4M2.51%-350,000Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,911,433 shares; 2025Q1: 1,911,433 shares; 2025Q2: 1,911,433 shares; 2025Q3: 2,418,476 shares; 2025Q4: 1,889,445 shares; 2026Q1: 1,918,970 shares; 2026Q2: 1,425,000 shares; 2026Q3: 925,000 shares 925,000$29.3M2.27%-500,000Timeline
SRZNSURROZEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 885,000 shares 885,000$28.5M2.21%newTimeline
KRSAKORSANA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 877,022 shares 877,022$28.1M2.17%newTimeline
SGMTSAGIMET BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 2,757,742 shares 2,757,742$27.2M2.11%newTimeline
DFTXDEFINIUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,000,000 shares; 2026Q2: 2,000,000 shares; 2026Q3: 700,000 shares 700,000$26.6M2.06%-1,300,000Timeline
ADRXADARX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,260,577 shares 1,260,577$25.1M1.95%newTimeline
EDITEDITAS MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 8,889,000 shares; 2026Q3: 8,889,000 shares 8,889,000$22.8M1.77%0Timeline
ENTXENTERA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 7,352,941 shares 7,352,941$21.4M1.66%newTimeline
ATTOATTOVIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,160,000 shares 1,160,000$19.9M1.54%newTimeline
AGENAGENUS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,985,387 shares 1,985,387$19.7M1.53%newTimeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 750,000 shares; 2025Q3: 750,000 shares; 2025Q4: 750,000 shares; 2026Q1: 750,000 shares; 2026Q2: 250,000 shares; 2026Q3: 175,000 shares 175,000$19.6M1.52%-75,000Timeline
IFRXINFLARX NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 7,300,000 shares; 2026Q3: 9,268,220 shares 9,268,220$16.7M1.29%+1,968,220Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 483,000 shares; 2025Q1: 483,000 shares; 2025Q2: 483,000 shares; 2025Q3: 483,000 shares; 2025Q4: 483,000 shares; 2026Q1: 483,000 shares; 2026Q2: 1,018,319 shares; 2026Q3: 1,018,319 shares 1,018,319$15.6M1.21%0Timeline
ANTXAN2 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,333,713 shares; 2026Q2: 2,933,680 shares; 2026Q3: 2,933,680 shares 2,933,680$15.6M1.21%0Timeline
IPSCCENTURY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 8,695,652 shares; 2026Q2: 8,695,652 shares; 2026Q3: 8,695,652 shares 8,695,652$14.9M1.15%0Timeline
ZURAZURA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 3,250,000 shares; 2026Q2: 3,250,000 shares; 2026Q3: 3,250,000 shares 3,250,000$13.5M1.05%0Timeline
IKTINHIBIKASE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 5,925,000 shares; 2025Q1: 5,344,432 shares; 2025Q2: 5,397,488 shares; 2025Q3: 5,397,488 shares; 2025Q4: 5,397,488 shares; 2026Q1: 5,397,488 shares; 2026Q2: 5,397,488 shares; 2026Q3: 5,397,488 shares 5,397,488$11.1M0.86%0Timeline
ASMBASSEMBLY BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,000,000 shares; 2025Q4: 1,000,000 shares; 2026Q1: 1,000,000 shares; 2026Q2: 1,415,000 shares; 2026Q3: 461,922 shares 461,922$10.9M0.84%-953,078Timeline
PEPGPEPGEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,357,319 shares; 2025Q4: 3,400,000 shares; 2026Q1: 4,475,000 shares; 2026Q2: 4,475,000 shares; 2026Q3: 4,475,000 shares 4,475,000$10.8M0.84%0Timeline
SABSSAB BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 4,401,500 shares; 2025Q4: 4,401,500 shares; 2026Q1: 4,401,500 shares; 2026Q2: 2,870,000 shares; 2026Q3: 2,870,000 shares 2,870,000$9.1M0.7%0Timeline
RLMDRELMADA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 633,901 shares; 2026Q2: 1,425,000 shares; 2026Q3: 2,350,000 shares 2,350,000$8.86M0.69%+925,000Timeline
RACDRESEARCH ALLIANCE CORP IVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 500,000 shares 500,000$5.79M0.45%newTimeline
HLXCHELIX ACQUISITION CORP IIIQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 500,000 shares; 2026Q2: 500,000 shares; 2026Q3: 500,000 shares 500,000$5.31M0.41%0Timeline
JTTTJATT III ACQUISITION CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 400,000 shares 400,000$4.41M0.34%newTimeline
TCGXTCGX ACQUISITION CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 300,000 shares 300,000$3.75M0.29%newTimeline
LONALEONABIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 464,398 shares; 2026Q1: 464,398 shares; 2026Q2: 464,398 shares; 2026Q3: 464,398 shares 464,398$1.66M0.13%0Timeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
TNGXTANGO THERAPEUTICS INC2,250,000$70.3Mshares
EYPTEYEPOINT INC4,600,000$65.8Mshares
DMRADAMORA THERAPEUTICS INC1,939,000$50.4Mshares
CATXPERSPECTIVE THERAPEUTICS INC6,336,782$21.6Mshares
NUVLNUVALENT INC100,000$12.3Mshares
RACCRESEARCH ALLIANCE CORP III500,000$5.35Mshares
VTGNVISTAGEN THERAPEUTICS INC2,788,620$630Kshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001831942-26-000052 base2026-11-16

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13G/A 0001831942-26-000056 JTTT2026-11-16
13G/A 0001831942-26-000055 RACD2026-11-16
13G/A 0001831942-26-000054 AMLX2026-11-16
13G/A 0001831942-26-000053 LBRX2026-11-16
13F-HR 0001831942-26-000052 Quarter ended 2026-09-302026-11-16
13G/A 0001831942-26-000051 VTGN2026-11-16
13G/A 0001831942-26-000050 EYPT2026-11-16
13G/A 0001831942-26-000049 CATX2026-11-16
13G/A 0001831942-26-000048 ANTX2026-11-16
13G/A 0001831942-26-000047 IFRX2026-11-16
13G 0001831942-26-000046 MTRI2026-11-13
13G 0001831942-26-000045 SGMT2026-10-07
13G 0001831942-26-000044 SRZN2026-10-01
13F-HR 0001831942-26-000033 Quarter ended 2026-06-302026-08-14acceptance time not in the bulk data set
13F-HR 0001831942-26-000025 Quarter ended 2026-03-312026-05-15acceptance time not in the bulk data set
13F-HR 0001831942-26-000004 Quarter ended 2025-12-312026-02-17acceptance time not in the bulk data set
13F-HR 0001831942-25-000023 Quarter ended 2025-09-302025-11-14acceptance time not in the bulk data set
13F-HR 0001831942-25-000008 Quarter ended 2025-06-302025-08-14acceptance time not in the bulk data set
13F-HR 0001831942-25-000005 Quarter ended 2025-03-312025-05-15acceptance time not in the bulk data set
13F-HR 0001831942-25-000002 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set
13F-HR 0001831942-24-000009 Quarter ended 2024-09-302024-11-14acceptance time not in the bulk data set
13F-HR 0001880562-24-000002 Quarter ended 2024-06-302024-08-14acceptance time not in the bulk data set
13F-HR 0001831942-24-000006 Quarter ended 2024-03-312024-05-15acceptance time not in the bulk data set
13F-HR/A 0001831942-24-000003 Quarter ended 2023-12-312024-02-14acceptance time not in the bulk data set
13F-HR 0001831942-24-000002 Quarter ended 2023-12-312024-02-14acceptance time not in the bulk data set
13F-HR 0001831942-23-000011 Quarter ended 2023-09-302023-11-14acceptance time not in the bulk data set
13F-HR 0001831942-23-000009 Quarter ended 2023-06-302023-08-14acceptance time not in the bulk data set
13F-HR 0001831942-23-000007 Quarter ended 2023-03-312023-05-15acceptance time not in the bulk data set
13F-HR 0001831942-23-000005 Quarter ended 2022-12-312023-02-14acceptance time not in the bulk data set
13F-HR 0001831942-22-000007 Quarter ended 2022-09-302022-11-14acceptance time not in the bulk data set
13F-HR 0001831942-22-000006 Quarter ended 2022-06-302022-08-15acceptance time not in the bulk data set
13F-HR 0001831942-22-000004 Quarter ended 2022-03-312022-05-16acceptance time not in the bulk data set
13F-HR 0001831942-22-000002 Quarter ended 2021-12-312022-02-14acceptance time not in the bulk data set
13F-HR 0001831942-21-000008 Quarter ended 2021-09-302021-11-15acceptance time not in the bulk data set
13F-HR/A 0001831942-21-000007 Quarter ended 2021-06-302021-10-14acceptance time not in the bulk data set
13F-HR/A 0001831942-21-000006 Quarter ended 2021-03-312021-10-14acceptance time not in the bulk data set
13F-HR 0001831942-21-000005 Quarter ended 2021-06-302021-08-16acceptance time not in the bulk data set
13F-HR 0001831942-21-000003 Quarter ended 2021-03-312021-05-17acceptance time not in the bulk data set
13F-HR 0001831942-21-000002 Quarter ended 2020-12-312021-02-16acceptance time not in the bulk data set